The U.S. FDA has approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes. Manufactured by Eli Lilly, Mounjaro targets two hormones, GIP and GLP-1, which help lower blood sugar levels. Clinical trials showed that Mounjaro is more effective at controlling blood sugar than other diabetes medications. Additionally, many participants in the trials experienced significant weight loss, with some losing between 12 and 25 pounds on average. Although Mounjaro is not officially approved for weight loss, Eli Lilly is seeking approval for this use. The medication is administered once a week using an auto-injector pen and will be available in six different doses. Common side effects include nausea, vomiting, and abdominal pain. There is also a warning about the potential risk of thyroid tumors, so it should not be used by individuals with a history of thyroid cancer.